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We have demonstrated that treating diet-induced obese (DIO) mice with the vasopeptidase inhibitor ilepatril improved neural
function. Vasopeptidase inhibitors block angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) activity. We
propose that increased activity of ACE and NEP contributes to pathophysiology of DIO. To address this issue C57Bl/6J mice or
mice deﬁcient in NEP were fed a high-fat diet and treated with ilepatril, enalapril, ACE inhibitor, or candoxatril, NEP inhibitor,
using both prevention and intervention protocols. Endpoints included glucose utilization and neural function determination. In
the prevention study glucose tolerance was impaired in DIO C57Bl/6J mice and improved with ilepatril or enalapril. Sensory
nerve conduction velocity, thermal nociception, and intraepidermal nerve ﬁber density were impaired in DIO C57Bl/6J mice
and improved with ilepatril or candoxatril. In the intervention study only enalapril improved glucose tolerance. Sensory nerve
conduction velocity and intraepidermal nerve ﬁber density were improved by all three treatments, whereas thermal nociception
was improved by ilepatril or candoxatril. In NEP-deﬁcient mice DIO impaired glucose utilization and this was improved with
enalapril. Nerve function was not impaired by DIO in NEP-deﬁcient mice. These studies suggest that ACE and NEP play a role in
pathophysiology associated with DIO.
1.Introduction
Previously we reported that deletion of neutral endopepti-
dase (NEP) provides protection from obesity- and diabetes-
induced neural complications [1]. We have also shown that
treating obese and streptozotocin-diabetic mice with the
vasopeptidase inhibitor ilepatril prevented neural complica-
tions including slowing of nerve conduction velocity, ther-
mal hypoalgesia, and decreased intraepidermal nerve ﬁber
density [2]. Vasopeptidase inhibitors are drugs that simul-
taneously inhibit NEP and angiotensin-converting enzyme
(ACE) activity [3]. Recent studies have shown increased
expression of angiotensin-II-forming enzymes in adipose
tissue and increased activity of the renin-angiotensin system
beingimplicatedinthedevelopmentofinsulinresistanceand
type 2 diabetes [4]. NEP is found in many tissues including
vascular and renal tissue and its activity is increased by fatty
acids and glucose in human microvascular cells [5–9]. In the
peripheral nervous system NEP is located in Schwann cell
membranessurroundingdorsalrootganglioncellsandnerve
ﬁbers [10, 11]. NEP degrades many vaso- and neuroactive
peptides including natriuretic peptides, adrenomedullin,
bradykinin, and calcitonin-gene-related peptide [12, 13].
Therefore, inhibition of ACE and NEP activity would be
expected to improve vascular and neural function. In this
regard we have demonstrated that treating type 1 and type
2d i a b e t i cr a t sa sw e l la sag e n e t i cr a tm o d e lo fo b e s i t yw i t h
ilepatril improves vascular and neural dysfunction [14–16].2 Journal of Obesity
However, little information is available about the eﬀect of
vasopeptidase inhibitors in animal models of diet-induced
obesity.
In order to further elucidate the eﬀects of vasopeptidase
inhibitors in peripheral nerve dysfunction associated with
obesity we examined the eﬀect of diet-induced obesity on
nerve conduction velocity and thermal response latency in
the hindpaw of C57Bl/6J mice and mice deﬁcient in NEP
treated with ilepatril, enalapril, ACE inhibitor, or candoxa-
tril, NEP inhibitor [1, 2].
2.MaterialsandMethods
Unless stated otherwise all chemicals used in these studies
were obtained from Sigma Chemical Co. (St. Louis, MO).
2.1.Animals. C57Bl/6JJwild-typemicewerepurchasedfrom
Jackson Laboratories. Breeding pairs of neutral endopep-
tidase-deﬁcient(NEP
−/−)mic ewer epr o videdb yDrs.L uand
GerardandareontheC57Bl/6Jbackground[17].Thesemice
have been bred and a colony created at the Veterans Aﬀairs
Medical Center, Iowa City, IA. The C57Bl/6J and NEP
−/−
mice were age-matched for these studies. Deﬁciency of NEP
activity was conﬁrmed in NEP
−/− mice by measuring the
speciﬁc activity of NEP in kidney homogenates using the
method described by Ayoub and Melzig [18] with modiﬁca-
tion. Activity of NEP in kidney from C57Bl/6J and NEP
−/−
mice was 0.35 ± 0.02 and 0.02 ± 0.02mM 7-amido-3-
methylcoumarin (AMC)/min/mg protein, respectively (P<
0.001 versus C57Bl/6J by unpaired t-test). This test was
performed on all mice used in these studies in order to
conﬁrm that NEP was functionally “knocked out” in the
NEP
−/− mice.
Mice were housed in a certiﬁed animal care facility and
food (Harlan Teklad, no. 7001, Madison, WI) and water
were provided ad libitum. Adequate measures were taken to
minimize pain or discomfort and all of the experiments were
conducted in accordance with international standards on
animal welfare and were compliant with all institutional and
National Institutes of Health guidelines for use of animals
(ACURF protocol 1101009).
The study design consisted of prevention and interven-
tion protocols. For the prevention protocol C57Bl/6J and
NEP
−/− miceat12weeksofageweredividedintoﬁvegroups.
Onegroupwasfedastandardchowdiet.Asecondgroupwas
fed a high-fat diet containing 24gm% fat, 24gm% protein,
and 41gm% carbohydrate (D12451; Research Diets, New
Brunswick, NJ). The primary source of the increased fat
content in the diet was soybean oil and lard. The control
and high-fat diet contained 0.4 and 0.3% sodium chloride,
respectively. The average fat content of the control diet was
4.25gm%(HarlanTeklad,no.7001,Madison,WI).Thethird
through ﬁfth groups were fed the high-fat diet containing
ilepatril (500mg/kg in the diet), candoxatril (30mg/kg in the
diet), or enalapril (500mg/kg in the diet). These diets were
prepared by Research Diets and we provided the drugs. We
have found that these doses provide maximal inhibition of
NEP and/or ACE activity in vivo [2, 19]. The experimental
period lasted twelve weeks. For the intervention study the
same ﬁve groups of C57Bl/6J and NEP
−/− mice at 12 weeks
of age were fed the control diet (group 1) or high-fat diet
(groups 2–5) for 12 weeks. Afterwards, the four groups of
high-fat-fed mice were fed a high-fat diet with no additions
(group2)orhigh-fatdietcontainingilepatril,candoxatril,or
enalapril (groups 3–5) for 12 weeks. The mice on the control
diet remained on the control diet.
2.2.IntraperitonealGlucoseToleranceTest. Afteranovernight
fast mice were injected with a saline solution containing
2g/kg glucose, i.p. Immediately prior to the glucose injec-
tion and for 120 minutes afterwards blood samples were
taken to measure circulating glucose levels with the use
of glucose-dehydrogenase-based reagent strips (Aviva Accu-
Chek, Roche, Mannheim, Germany) [2]. Blood samples
(0.6μL) were taken from a tail vein that was lanced once.
2.3. Thermal Nociceptive Response. Thermal nociceptive
response in the hindpaw was measured using the Hargreaves
method with instrumentation provided by IITC Life Science,
Woodland Hills, CA (model 390G) as previously described
[2]. The test was performed in a blind manner. Thermal
nociceptive responses were measured by placing the mouse
in the observation chamber on top of the thermal testing
apparatus and allowing it to acclimate to the warmed glass
surface (33◦C) and surroundings for a period of 15min. The
mobile heat source was maneuvered so that it was under the
heal of the hindpaw and then activated, a process that starts
a timer and locally warms the glass surface, when the mouse
withdrew its paw, the timer, and the heat source was turned
oﬀ [2]. Following an initial recording, which was discarded,
two measurements were made for each hindpaw, with a rest
period of 5min between each set of measurements. The
mean of the measurements, reported in seconds, was used
as a measure of the thermal nociceptive response latency.
2.4. Sensory Nerve Conduction Velocity. Mice were anes-
thetized with Nembutal (75mg/kg, i.p., Abbott Laboratories,
North Chicago, IL) and sensory nerve conduction velocities
were determined as previously described [1, 2]. Brieﬂy,
sensory nerve conductionvelocity was recorded in the digital
nerve to the second toe by stimulating with a square-wave
pulse of 0.05ms duration using the smallest intensity current
that resulted in a maximal amplitude response (Grass S44
Stimulator; Grass Medical Instruments, Quincy, MA). The
sensory nerve action potential was recorded behind the
medial malleolus. The maximal sensory nerve conduction
velocity was calculated by measuring the latency to the
onset/peak of the initial negative deﬂection and the distance
between stimulating and recording electrodes (measured
in millimeters using a Vernier caliper). The sensory nerve
conduction velocity was reported in meters per second.
2.5. Intraepidermal Nerve Fiber Density. Immunoreactive
intraepidermalnerveﬁberproﬁleswerevisualizedusingcon-
focalmicroscopyaspreviouslydescribed[2].Biopsies ofskin
of the right hindpaw were ﬁxed, dehydrated, and embedded
in paraﬃn. Sections (7μm) were collected and immunos-
tained with anti-PGP9.5 antibody (rabbit anti-human no.Journal of Obesity 3
Table 1: Prevention study in C57Bl/6 and NEP−/− mice. Eﬀect of high fat diet +/− ilepatril, candoxatril, or enalapril on change in body
weight, blood glucose, and epididymal fat mass.
Determination Control High fat High fat + ilepatril High fat + candoxatril High fat + enalapril
C57Bl/6 mice (12) (11) (12) (12) (10)
Start body weight (g) 27.5 ± 0.4 26.7 ± 0.5 27.2 ± 0.6 26.3 ± 0.5 27.0 ± 0.5
End body weight (g) 32.2 ± 0.6 42.9 ± 1.4a 29.0 ± 0.9b,c 45.3 ± 0.7a 29.3 ± 0.5b,c
Blood glucose (mg/dL) 188 ± 7 183 ± 8 152 ± 8 214 ± 19 177 ± 10
Epididymal fat pad (g) 0.31 ± 0.05 0.95 ± 0.08a 0.29 ± 0.05b,c 1.13 ± 0.08a 0.16 ± 0.02b,c
Fat pad/ﬁnal body
weight (%) 0.95 ± 0.14 2.21 ± 0.18a 0.98 ± 0.15b,c 2.52 ± 0.21a 0.54 ± 0.07b,c
NEP−/− mice (12) (16) (12) (14) (14)
Start body weight (g) 24.5 ± 0.6 25.6 ± 0.4 24.2 ± 0.6 25.1 ± 0.9 25.7 ± 0.5
End body weight (g) 29.1 ± 0.6 42.1 ± 1.3a 27.1 ± 1.1b,c 43.8 ± 2.1a 27.3 ± 0.8b,c
Blood glucose (mg/dL) 139 ± 8 153 ± 8 148 ± 10 173 ± 12 163 ± 6
Epididymal fat pad (g) 0.24 ± 0.03 1.09 ± 0.06a 0.19 ± 0.02b,c 0.90 ± 0.04a 0.21 ± 0.06b,c
Fat pad/ﬁnal body
weight (%) 0.80 ± 0.09 2.62 ± 0.13a 0.70 ± 0.07b,c 2.13 ± 0.15a 0.60 ± 0.05b,c
Data are presented as the mean ± SEM. aP < 0.05 compared to control; bP < 0.05 compared to high fat; cP < 0.05 compared to candoxatril. Parentheses
indicate the number of experimental animals in each group.
7863-0504(thisantibodycross-reactswithrat,mouseguinea
pig, and other species), AbD Serotic, Morpho Sys US
Inc., Raleigh, NC) overnight followed by treatment with
secondary antibody Alexa Fluor 546 goat anti-rabbit (Invit-
rogen, Eugene, OR). Proﬁles were imaged using a Zeiss
710 confocal microscope with a 40x objective and were
counted by two individual investigators that were blinded to
the sample identity. All immunoreactive proﬁles within the
epidermis were counted and normalized to epidermal length
[20]. Length of the epidermis was determined by drawing a
polyline along the contour of the epidermis and recording
its length in mm. The number of intraepidermal nerve ﬁber
proﬁles was reported per mm length.
2.6. Data Analysis. The results are presented as mean ± SE.
Comparisons between the groups for body weight, blood
glucose, sensory nerve conduction velocity, thermal nocicep-
tion, and intraepidermal nerve ﬁber proﬁles were conducted
using a one-way ANOVA and Bonferroni’s test for multiple
comparisons (Prism software; GraphPad, San Diego, CA). A
P value of less 0.05 was considered signiﬁcant.
3. Results
3.1. Eﬀect of High-Fat Diet and Treatment on Weight and
Blood Glucose Levels. Presented in Table 1 are weight and
blood glucose changes for C57/Bl6J and NEP
−/− mice used
in the prevention study. At 12 weeks of age the beginning
body weights of C57Bl/6J and NEP
−/− mice were similar.
When fed a high-fat diet C57Bl/6J and NEP
−/− mice both
gained a similar amount of weight. Treating the high-fat
diet with ilepatril or enalapril but not candoxatril completely
prevented the gain in weight. The mass of the epididymal
fat pad was signiﬁcantly increased in high-fat-fed mice and
mice fed the high-fat diet treated with candoxatril compared
to control mice or mice fed the high-fat diet containing
ilepatril or enalapril. When calculating the epididymal fat
pad mass as a percent of total body weight epididymal fat
padmasswassigniﬁcantlyincreasedinhigh-fat-fedC57Bl/6J
mice and mice fed a high-fat diet containing candoxatril
compared to control. Treating the high-fat diet with ilepatril
and to a greater extent enalapril prevented the increase in
epididymal fat pad mass when presented as percent of ﬁnal
body weight. Similar results were obtained with NEP
−/−
mice. Nonfasting blood glucose levels were not signiﬁcantly
diﬀerent between C57Bl/6J and NEP
−/− mice fed the control
or high-fat diets and not aﬀected by ilepatril, candoxatril, or
enalapril treatment.
In the intervention study all mice fed the high-fat diet
for the initial 12 weeks of the experimental design gained
a signiﬁcant amount of weight (Table 2). When transferred
to a high-fat diet containing ilepatril or enalapril for an
additional 12 weeks C57Bl/6J and NEP
−/− mice lost weight.
Mice remaining on the high diet or high-fat diet containing
candoxatril continued to gain weight. The epididymal fat
mass decreased after C57Bl/6J or NEP
−/− mice, fed a diet
containing high fat for 12 weeks, were given a high-fat
diet containing enalapril. The epididymal fat mass also was
decreased after NEP
−/− mice but not C57Bl/6J mice were
fed a high-fat diet treated with ilepatril. Treating high-fat-fed
C57Bl/6J or NEP
−/− mice with candoxatril did not reduce
epididymal fat mass. A similar trend was observed when the
epididymal fat mass data was presented as percentage of
ﬁnal body weight. Nonfasting blood glucose levels were not
changed in C57Bl/6J or NEP
−/− mice fed control or high-fat
diets with or without ilepatril, candoxatril, or enalapril.
3.2. Eﬀect of High-Fat Diet and Treatment on Glucose Tol-
erance. In the prevention study C57Bl/6J (Figure 1)a n d
NEP
−/− (Figure 2) mice fed the high-fat diet or high-fat diet
containing candoxatril had an impaired glucose clearance
curve compared to control mice. In contrast, the glucose4 Journal of Obesity
Table 2: Intervention study in C57Bl/6 and NEP−/− mice. Eﬀect of high fat diet+/− ilepatril, candoxatril, or enalapril on change in body
weight, blood glucose, and epididymal fat mass.
Determination Control High fat High fat + ilepatril High fat + candoxatril High fat + enalapril
C57Bl/6 mice (23) (23) (12) (11) (12)
Start Body Weight (g) 27.3 ± 0.3 26.9 ± 0.4 26.6 ± 0.3 27.9 ± 0.6 27.3 ± 0.6
12 week Weight (g) 31.8 ± 0.3 44.9 ± 0.8a 46.4 ± 1.2a 44.2 ± 1.4a 44.2 ± 1.3a
End Body Weight (g) 36.6 ± 0.4 49.1 ± 1.1a,d 43.3 ± 1.8a,b 52.2 ± 1.6a,d 33.7 ± 0.9b,d
Blood glucose (mg/dL) 170 ± 9 168 ± 11 156 ± 9 149 ± 11 192 ± 10
Epididymal fat pad (g) 0.45 ± 0.04 0.85 ± 0.05a 1.06 ± 0.09a 0.92 ± 0.04a 0.57 ± 0.06b
Fat pad/Final body
weight (%) 1.36 ± 0.10 1.75 ± 0.11a,c 2.43 ± 0.15a,b 1.87 ± 0.13a 1.67 ± 0.14c
NEP−/− mice (9) (10) (9) (10) (10)
Start Body Weight (g) 26.4 ± 0.4 27.6 ± 1.0 26.1 ± 1.2 26.2 ± 1.1 25.8 ± 0.4
12 week Weight (g) 28.0 ± 0.5 36.8 ± 2.1a 34.7 ± 1.4a 36.4 ± 1.2a 34.8 ± 1.5a
End Body Weight (g) 30.4 ± 0.8 50.7 ± 1.9a,d 29.8 ± 0.8b 50.3 ± 1.2a,d 30.5 ± 1.0b
Blood glucose (mg/dL) 141 ± 7 172 ± 16 173 ± 8 163 ± 10 184 ± 13
Epididymal fat pad (g) 0.23 ± 0.06 0.83 ± 0.03a 0.45 ± 0.05b 0.86 ± 0.04a 0.48 ± 0.08b
Fat pad/Final body
weight (%) 0.73 ± 0.17 1.64 ± 0.07a 1.48 ± 0.15a 1.71 ± 0.07a 1.53 ± 0.19a
Data are presented as the mean ± SEM. aP < 0.05 compared to control; bP < 0.05 compared to high fat; cP < 0.05 compared to ilepatril; dP < 0.05 compared
to 12 week animals. Parentheses indicate the number of experimental animals in each group.
clearance curve was near normal in C57Bl/6J and NEP
−/−
mice fed a high-fat diet containing ilepatril or enalapril.
In the intervention study feeding C57Bl/6J (Figure 3)o r
NEP
−/− (Figure 4) mice for 24 weeks a high-fat diet caused
an impaired glucose clearance curve. Treating high-fat-fed
C57Bl/6J or NEP
−/− mice with enalapril for the last 12 weeks
of the 24-week period partially corrected glucose utilization.
Treating NEP
−/− mice with ilepatril also partially corrected
glucose utilization (Figure 4). Treating C57Bl/6J mice with
ilepatril did not improve glucose utilization nor did treating
C57Bl/6J or NEP
−/− with candoxatril.
3.3. Eﬀect of High-Fat Diet on Sensory Nerve Conduction
Velocity,ThermalNociception,andIntraepidermalNerveFiber
Proﬁle Density. Data in Figure 5 (left) demonstrate that sen-
sory nerve conduction velocity was signiﬁcantly decreased in
high-fat-fed C57Bl/6J mice compared to control mice and
that this was prevented by treating high-fat-fed mice with
Ilepatril or candoxatril using a prevention protocol. Data
in Figure 5 (center) demonstrate that thermal nociception
was signiﬁcantly decreased in C57Bl/6J mice after 12 weeks
of a high-fat diet compared to control mice as indicated
by an increase in paw withdrawal latency. Treatment with
ilepatril or candoxatril and to a lesser extent enalapril for
the 12-week period prevented thermal hypoalgesia in high-
fat-fed C57Bl/6J mice. Data in Figure 5 (right) demonstrate
that the number of intraepidermal nerve ﬁber proﬁles was
signiﬁcantly decreased in high-fat-fed C57Bl/6J mice and
that treatment of these mice with ilepatril or candoxatril but
not enalapril for 12 weeks prevented the signiﬁcant decrease.
Sensory nerve conduction velocity, thermal nociception, and
intraepidermal nerve ﬁber density were not impaired in
NEP
−/− mice fed a high-fat diet (Figure 6, left, center, and
right, resp.).
We also determined the eﬀect of treating high-fat-fed
C57Bl/6J and NEP
−/− mice using an intervention protocol
(Figures 7 and 8, resp.). In this study design high-fat-fed
mice were untreated for 12 weeks followed by 12 weeks of
a high-fat diet with or without treatment. Feeding C57Bl/6J
mice a high-fat diet for 24 weeks caused a signiﬁcant
decreaseinsensorynerveconductionvelocity(Figure 7,left).
Treating these mice for the last 12 weeks of the 24-week
period with ilepatril, candoxatril, or enalapril reversed the
slowing of sensory nerve conduction velocity. The decrease
in thermal nociception in high-fat-fed C57Bl/6J mice was
reversedbytreatingmicewithilepatrilorcandoxatrilbutnot
enalapril (Figure 7, center). Treating high-fat-fed C57Bl/6J
mice with ilepatril, candoxatril, or enalapril reversed the
decrease in intraepidermal nerve ﬁber proﬁles (Figure 7,
right). Feeding NEP
−/− mice a high-fat diet for 24 weeks
with or without treatment had no eﬀect on sensory nerve
conduction velocity, thermal nociception, or intraepidermal
nerve ﬁber density (Figure 8, left, center, and right, resp.).
4. Discussion
The main ﬁndings from these studies were that diet-
induced obesity caused signiﬁcant weight gain and impaired
glucose utilization in C57Bl/6J and NEP
−/− mice that was
improved when the mice were treated with ilepatril or
enalapril using a prevention protocol. Using the intervention
protocol enalapril but not ilepatril treatment was eﬀective
improving glucose utilization by C57Bl/6J mice. Treating
C57Bl/6J or NEP
−/− mice with candoxatril did not improveJournal of Obesity 5
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Figure 1: Plasma glucose concentration curve during intraperi-
toneal glucose tolerance test (IPGTT) for C57Bl/6J mice fed a
normal or high-fat-containing diet with or without ilepatril, can-
doxatril, or enalapril for 12 weeks (prevention protocol). Data are
the mean ± SEM in mM. Fasting basal blood glucose levels were
121 ± 8, 143 ± 9, 138 ± 4, 175 ± 5, and 116 ± 7mg/dL for control,
high fat, high fat + ilepatril, high fat + candoxatril, and high fat +
enalapril, respectively. Control (closed circles), high fat (open
circles), high fat + ilepatril (closed innervated triangle), high fat +
candoxatril (open triangle), and high fat + enalapril (closed
rectangle). The area under the curve (AUC) was signiﬁcantly
diﬀerent P<0.01 for high-fat-fed mice versus control and high-
fat-fed mice treated with candoxatril versus control. There was no
signiﬁcant diﬀerence for AUC between mice fed a high-fat diet
containing ilepatril or enalapril versus control. The number of mice
in each group was the same as shown in Table 1.
weight gain or glucose utilization. These data suggest that
inhibition of ACE and not NEP activity was responsible
for improving weight gain and glucose utilization in high-
fat-fed mice. Diet-induced obesity also caused slowing of
sensory nerve conduction velocity, thermal hypoalgesia, and
decrease in epidermal nerve ﬁber density in the paw of
the hindlimb in C57Bl/6J mice but not NEP
−/− mice. The
impairment in sensory nerve function endpoints in C57Bl/6J
mice fed a high-fat diet was prevented/improved when the
mice were treated with ilepatril or candoxatril and to a
much lesser extent enalapril using either the prevention or
intervention protocol. These data suggestthat increased NEP
activity/expression but not ACE activity contributes to diet-
induced obesity-related deﬁcits in sensory nerve function.
Previous studies have shown that diet-induced obesity
in rodent models can be prevented by ACE inhibitors and
angiotensin II receptor blockers [21–24]. In addition, diet-
induced weight gain and fat mass are reduced, energy
expenditure increased, and glucose tolerance improved in
mice lacking ACE or the angiotensin II type 1a receptor
[25, 26]. The mechanisms proposed for the improve-
ment in obesity and glucose tolerance with treatment of
rodent models with ACE inhibitors are increased energy
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Figure 2: Plasma glucose concentration curve during intraperi-
tonealglucosetolerancetest(IPGTT)forNEP
−/− micefedanormal
or high-fat-containing diet with or without ilepatril, candoxatril,
or enalapril for 12 weeks (prevention protocol). Data are the mean
± SEM in mM. Fasting basal blood glucose levels were 113 ± 5,
112 ± 3, 120 ± 8, 148 ± 6, and 119 ± 6mg/dL for control, high fat,
high fat + ilepatril, high fat + candoxatril, and high fat + enalapril,
respectively. Control (closed circles), high fat (open circles), high
fat + ilepatril (closed innervated triangle), high fat + candoxatril
(open triangle), and high fat + enalapril (closed rectangle). The
area under the curve (AUC) was signiﬁcantly diﬀerent P<0.01
and P<0.05 for high-fat-fed mice versus control and high-fat-fed
micetreatedwithcandoxatrilversuscontrol,respectively.Therewas
no signiﬁcant diﬀerence for AUC between mice fed a high-fat diet
containing ilepatril or enalapril versus control. The number of mice
in each group was the same as shown in Table 1.
expenditure, liver and adipose tissue metabolic modulation,
lower concentration of leptin, improved insulin signaling,
and increased glucose and fatty acid utilization by muscle
[21–30]. In a study comparing the eﬀects of Ramipril, an
ACE inhibitor, to ilepatril in JCR:LA-cp rats, an obese,
insulin-resistant, hyperinsulinemic, normoglycemic model,
it was found that both compounds reduced the surge of
plasma insulin in a meal tolerance test by about 50% but
ilepatril was more beneﬁcial in improving vascular reactivity
[31].Inourstudywefoundthatenalapriltrendedtobemore
eﬀectivethanilepatrilpreventing/reducingfatpadmass.This
could be because enalapril at the dosage used was a more
eﬀective ACE inhibitor than ilepatril in target tissues. In
another study using obese Zucker rats it was found that
dual inhibition of ACE and NEP improved insulin-mediated
glucose disposal more eﬀectively than monotherapy and
this eﬀect was linked to increased activation of the kinin-
nitric oxide pathway [32]. In a similar independent study
it was found that Omapatrilat, a vasopeptidase inhibitor,
induced insulin sensitization and increased myocardial glu-
coseuptakeinobeseZuckerratsandthattheeﬀectofOmap-
atrilatwasgreaterthanRamiprilinpartduetostimulationof
theB2 receptor [33].Laterthisgroupreportedthattreatment6 Journal of Obesity
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Figure 3: Plasma glucose concentration curve during intraperi-
toneal glucose tolerance test (IPGTT) for C57Bl/6J mice fed a
normal or high-fat-containing diet for 24 weeks and the high-fat
diet with or without ilepatril, candoxatril, or enalapril for the last
12weeks(interventionprotocol).Dataarethemean ±SEMinmM.
Fasting basal blood glucose levels were 111 ± 5, 148 ± 5, 177 ± 11,
147±6, and 134±8mg/dL for control, high fat, high fat + ilepatril,
highfat+candoxatril,andhighfat+enalapril,respectively.Control
(closed circles), high fat (open circles), high fat + ilepatril (closed
innervated triangle), high fat + candoxatril (open triangle), and
high fat + enalapril (closed rectangle). The area under the curve
(AUC) was signiﬁcantly diﬀerent P<0.05 for high-fat-fed mice
versus control and high-fat-fed mice treated with ilepatril versus
control. There was no signiﬁcant diﬀerence for AUC between
mice fed a high-fat diet containing candoxatril or enalapril versus
control. The number of mice in each group was the same as shown
in Table 2.
of obese Zucker rats with a vasopeptidase inhibitor increased
muscle glucose uptake independent of insulin signaling
[34]. In two of these studies protection of bradykinin from
degradation by NEP was found to improve insulin action
[32, 33]. Interestingly, it has been shown that natriuretic
peptides promote muscle mitochondrial biogenesis and fat
oxidation as to prevent obesity and glucose intolerance [35].
The natriuretic peptides are also degraded by NEP [36].
Because NEP is expressed in skeletal muscle in relatively
large amounts and being located on the cell surface, NEP is
able to hydrolyze peptides in the vicinity of their receptors
thereby neutralizing their bioactivity [34, 36]. However,
inhibition of ACE may also lead to protection of bradykinin
levels by inhibiting kininase-II-mediated degradation of
this nonapeptide [37]. Henriksen et al. [38] reported that
ACE inhibition by captopril improved glucose transport
in insulin-resistant muscle of the obese Zucker rat. They
attributed the improvement to modulation of insulin action
by bradykinin mediated through B2 receptors and by an
increase in nitric oxide production. Since bradykinin and
natriuretic peptides may have a role in enhancing insulin
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Figure 4: Plasma glucose concentration curve during intraperi-
tonealglucosetolerancetest(IPGTT)forNEP
−/− micefedanormal
or high-fat-containing diet for 24 weeks and the high-fat diet with
or without ilepatril, candoxatril, or enalapril for the last 12 weeks
(intervention protocol). Data are the mean ± SEM in mM. Fasting
basal blood glucose levels were 110 ± 7, 131 ± 5, 138 ± 5, 140 ± 8,
and 130 ± 7mg/dL for control, high fat, high fat + ilepatril, high
fat + candoxatril, and high fat + enalapril, respectively. Control
(closed circles), high fat (open circles), high fat + ilepatril (closed
innervated triangle), high fat + candoxatril (open triangle), and
high fat + enalapril (closed rectangle). The area under the curve
(AUC) was signiﬁcantly diﬀerent P<0.01 for high-fat-fed mice
versus control and high fat-fed-mice treated with candoxatril versus
control. There was no signiﬁcant diﬀerence for AUC between
mice fed a high fat-diet containing ilepatril or enalapril versus
control. The number of mice in each group was the same as shown
in Table 2.
action and regulating glucose and fatty acid metabolism
by muscle protecting their bioactive function by preventing
degradation through inhibition of ACE and/or NEP may be
a therapeutic approach for treatment of obesity and insulin
resistance [34, 36, 38].
We have previously shown that treating diabetic rats
with enalapril improved vascular and nerve endpoints but
enalapril was less eﬀective in rats fed a high-fat diet [19,
36, 39, 40]. In contrast, we found that treating obese or
diabetic rats with ilepatril was more eﬀective than enalapril
in improving peripheral nerve dysfunction [19, 36, 40].
This was attributed to be due to improvement in vascular
function. We have shown that treating diabetic or diet-
induced obese rodents with ilepatril improves vasodilation
of blood vessels that provide circulation to the sciatic nerve
by reducing oxidative stress and preventing degradation of
vasoactivepeptides by NEP including calcitonin gene-related
peptide and C-type natriuretic peptide thereby maintaining
endoneurial blood ﬂow and preventing ischemia [36]. Since
NEP degrades both calcitonin gene-related peptide and
substance P, peptides important in pain signaling pathways,Journal of Obesity 7
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Figure 5: Sensory nerve conduction velocity, thermal nociception, and intraepidermal nerve ﬁber proﬁles for C57Bl/6J mice fed a normal
or high-fat-containing diet with or without ilepatril, candoxatril, or enalapril for 12 weeks (prevention protocol). Control (open bar), high
fat (right hatch bar), high fat + ilepatril (left hatch bar), high fat + candoxatril (cross hatch bar), and high fat + enalapril (closed bar). Data
are the mean ± SEM. The number of mice in each group was the same as shown in Table 1.a ,P<0.05 versus control; b, P<0.05 versus
high-fat-fed mice.
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Figure 6: Sensory nerve conduction velocity, thermal nociception, and intraepidermal nerve ﬁber proﬁles for NEP
−/− mice fed a normal
or high-fat-containing diet with or without ilepatril, candoxatril, or enalapril for 12 weeks (prevention protocol). Control (open bar), high
fat (right hatch bar), high fat + ilepatril (left hatch bar), high fat + candoxatril (cross hatch bar), and high fat + enalapril (closed bar). Data
are the mean ± SEM. The number of mice in each group was the same as shown in Table 1.a ,P<0.05 versus control; b, P<0.05 versus
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Figure 7: Sensory nerve conduction velocity, thermal nociception, and intraepidermal nerve ﬁber proﬁles for C57Bl/6J mice fed a normal
or high-fat-containing diet for 24 weeks with or without ilepatril, candoxatril, or enalapril for the last 12 weeks (intervention protocol).
Control (open bar), high fat (right hatch bar), high fat + ilepatril (left hatch bar), high fat + candoxatril (cross hatch bar), and high fat +
enalapril (closed bar). Data are the mean ± SEM. The number of mice in each group was the same as shown in Table 2.a ,P<0.05 versus
control; b, P<0.05 versus high-fat-fed mice.
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Figure 8: Sensory nerve conduction velocity, thermal nociception, and intraepidermal nerve ﬁber proﬁles for NEP
−/− mice fed a normal or
high-fat-containingdietfor24weekswithorwithoutilepatril,candoxatril,orenalaprilforthelast12weeks(interventionprotocol).Control
(open bar), high fat (right hatch bar), high fat + ilepatril (left hatch bar), high fat + candoxatril (cross hatch bar), and high fat + enalapril
(closed bar). Data are the mean ± SEM. The number of mice in each group was the same as shown in Table 2.a ,P<0.05 versus control; b,
P<0.05 versus high-fat-fed mice.Journal of Obesity 9
itislikelythatblockingNEPactivityormicedeﬁcientinNEP
would maintain higher levels of both of these neuroactive
peptides and perhaps be more sensitive to painful stimuli.
5. Conclusion
Data from clinical trials clearly suggest that activation of
therenin-angiotensin-aldosteronesystemplaysanimportant
role in the pathophysiology of the metabolic syndrome
through interaction of a wide range of physiological and
molecular mechanisms [41]. More recently in humans activ-
ity of NEP has been shown to correlate with body mass index
and measures of insulin resistance with increasing activity
found in subjects with multiple cardiovascular risk factors
[42]. In these studies we found that feeding mice a high-
fat diet causes weight gain, impaired glucose tolerance, and
sensory nerve dysfunction. Inhibition of ACE was eﬀective
in reducing weight gain and improving glucose utilization
but generally noneﬀective in improving sensory nerve dys-
function. In contrast, inhibition of NEP improved sensory
nerve dysfunction and had no eﬀect in improving weight
gain or glucose utilization. Treating high-fat-fed mice with
a vasopeptidase inhibitor improved weight gain, glucose uti-
lization, and sensory nerve function. Thus, we conclude that
increased activity of NEP is associated with sensory nerve
dysfunction in an animal model of diet-induced obesity and
that dual inhibition of ACE and NEP may be more eﬀec-
tive than monotherapy in reducing insulin resistance and
the sensory nerve complications associated with metabolic
syndrome.
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